Analysts See $-0.40 EPS for Rhythm Pharmaceuticals, Inc. (RYTM)

July 14, 2018 - By Tamara Reed

Analysts expect Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) to report $-0.40 EPS on August, 13.After having $-0.60 EPS previously, Rhythm Pharmaceuticals, Inc.’s analysts see -33.33 % EPS growth. The stock decreased 2.21% or $0.73 during the last trading session, reaching $32.31. About 181,064 shares traded. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) has 0.00% since July 14, 2017 and is . It has underperformed by 12.57% the S&P500.

Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. The company has market cap of $1.10 billion. The Company’s lead product candidate is Setmelanotide, a melanocortin-4 receptor agonist that is in Phase III clinical trials for treating POMC deficiency obesity and leptin receptor deficiency obesity; and Phase II clinical trials for treating Bardet-Biedl syndrome, Alstr??m syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders. It currently has negative earnings. The firm was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015.

More notable recent Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) news were published by: Globenewswire.com which released: “Rhythm Pharmaceuticals Completes Pivotal Enrollment in Two Ongoing Phase 3 Clinical Trials Evaluating …” on June 14, 2018, also Globenewswire.com with their article: “Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering” published on June 18, 2018, Nasdaq.com published: “Rhythm Pharmaceuticals, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to …” on June 25, 2018. More interesting news about Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) were released by: Globenewswire.com and their article: “Rhythm Pharmaceuticals Announces New Topline Clinical Data from Ongoing Phase 2 Basket Studies Evaluating …” published on June 18, 2018 as well as Benzinga.com‘s news article titled: “38 Stocks Moving In Tuesday’s Mid-Day Session” with publication date: June 19, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: